Abstract 35P
Background
Chemotherapy-induced alopecia is one of the most distressing symptoms for cancer patients undergoing cytotoxic chemotherapy. In this prospective two-center study, the objectives were to determine the efficacy and toxicity of a scalp-cooling device in the prevention of alopecia associated with chemotherapy.
Methods
Breast cancer patients who were planning for (neo)adjuvant chemotherapy consisting of taxane- and/or anthracycline- based regimens, with or without anti-HER2 therapy were invited to participate. They underwent a scalp cooling system offered by the Orbis Paxman Hair Loss Prevention System. The following were measured during the study: extent of hair loss based on Dean score (score ranges 0-4; 0-2 score reflects hair loss of 50% or less) 4 weeks after the completion of all cycles of chemotherapy, as determined by patients and independent assessors. Adverse events (AEs), specifically alopecia and potential study-related AEs, were graded according to NCI CTCAE v4.0.
Results
52 patients were enrolled into the study. 6 patients were excluded due to subjects’ own request (3), abnormal thyroid function (2) and anaemia (1). Of the remaining 46 patients, 50% each had taxane-based and taxane-anthracycline-based regimens. 3 of the 46 patients did not undergo any assessments after enrolment, resulting in 43 being assessable for outcomes. The median age was 51.5 years. A Dean score of 0-2 for hair loss was reported by 30.2% of the patients and 32.6% of the assessors. Only 4 patients (8.7%) did not require wearing headcover during the study. Alopecia grading were: grade 0 (9.3%), grade 1 (23.3%) and grade 2 (67.4%). Potential study-related AEs included dizziness [grade 1 (11.6%); grade 2 (2.3%)], headaches [grade 1 (4.7%)], complaint of cooling [grade 1 92.3%)]; there were no grade 3 or above toxicities.
Conclusions
In contrast to previous reports, the current scalp cooling system provided a lower efficacy in preventing alopecia in breast cancer patients also undergoing chemotherapy.
Acknowledgement: The scalp cooling system was provided by Orbis Paxman Hair Loss Prevention System.
Clinical trial identification
NCT4630080.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract